Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study

Nearly all mirikizumab-treated patients who achieved clinical remission at one year were not taking steroids INDIANAPOLIS, May 24, 2022 -- (Healthcare Sales & Marketing Network) -- In Eli Lilly and Company's (NYSE:LLY) pivotal, Phase 3 LUCENT-2 study, ... Biopharmaceuticals, Gastroenterology Eli Lilly, mirikizumab, ulcerative colitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news